TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer
Brief Summary: Critical limb ischemia (CLI) results from severe occlusive disease that impairs distal limb perfusion to the point where oxygen delivery is no longer adequate to meet the metabolic needs of the tissue, even under resting conditions. The limits of peripheral artery disease (PAD) compensatory mechanisms, such as distal vasodilatation and collateral formation, have been exceeded at this point. PAD is a widespread disease, affecting up to 15% of all adults older than 55 years. Formation of true new blood vessels, or angiogenesis, and development of collateral vessels from preexisting blood vessels, or arteriogenesis, is important in the pathophysiology of vascular disease. By stimulating these processes the investigators might be able to provide an alternative treatment strategy for patients with lower limb ischemia. In response to tissue injury and remodeling, neovascularization usually occurs via the proliferation and migration of progenitor endothelial cells (EPC) from preexisting vasculature. Indeed, recent studies have shown that bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation in patients with limb ischemia. So the investigators determine to evaluate the efficacy of repeated MNC transplantation in patients with ischemic lower limb.


Options:
A: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
D: Intervention Type: GENETIC; Name: Autologous peripheral blood CD34 positive cell therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer
Brief Summary: Critical limb ischemia (CLI) results from severe occlusive disease that impairs distal limb perfusion to the point where oxygen delivery is no longer adequate to meet the metabolic needs of the tissue, even under resting conditions. The limits of peripheral artery disease (PAD) compensatory mechanisms, such as distal vasodilatation and collateral formation, have been exceeded at this point. PAD is a widespread disease, affecting up to 15% of all adults older than 55 years. Formation of true new blood vessels, or angiogenesis, and development of collateral vessels from preexisting blood vessels, or arteriogenesis, is important in the pathophysiology of vascular disease. By stimulating these processes the investigators might be able to provide an alternative treatment strategy for patients with lower limb ischemia. In response to tissue injury and remodeling, neovascularization usually occurs via the proliferation and migration of progenitor endothelial cells (EPC) from preexisting vasculature. Indeed, recent studies have shown that bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation in patients with limb ischemia. So the investigators determine to evaluate the efficacy of repeated MNC transplantation in patients with ischemic lower limb.


Options:
A: Arm Label: autologous purified CD34+ cell; Type: EXPERIMENTAL; Interventions: Other: autologous purified CD34+ cells | Arm Label: autologous PB-MNC; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous peripheral blood mononuclear cells | Intervention Type: OTHER; Name: autologous purified CD34+ cells; Assigned to Arm(s): autologous purified CD34+ cell | Intervention Type: OTHER; Name: autologous peripheral blood mononuclear cells; Assigned to Arm(s): autologous PB-MNC
B: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
D: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care
Brief Summary: Overweight and obesity are highly significant clinical and public health issues, affecting more than two-thirds of adults in this country; however, primary care clinicians often do not document overweight or obesity or discuss weight management with their patients. The objectives of the proposed research are to develop and evaluate a set of tools within electronic health records (EHRs) to assist primary care clinicians with the diagnosis and treatment of overweight and obesity and to help patients manage their weight.


Options:
A: Arm Label: Healthy Lifestyle (Active Intervention); Type: OTHER; Interventions: Behavioral: Multiple behavior interventions | Arm Label: Healthy Drinks (Active Intervention); Type: OTHER; Interventions: Behavioral: Single behavior intervention | Arm Label: Social and Leadership Skills (Control Intervention); Type: OTHER; Interventions: Behavioral: Control Intervention unrelated to weight | Intervention Type: BEHAVIORAL; Name: Single behavior intervention; Assigned to Arm(s): Healthy Drinks (Active Intervention) | Intervention Type: BEHAVIORAL; Name: Multiple behavior interventions; Assigned to Arm(s): Healthy Lifestyle (Active Intervention) | Intervention Type: BEHAVIORAL; Name: Control Intervention unrelated to weight; Assigned to Arm(s): Social and Leadership Skills (Control Intervention)
B: Arm Label: Hospital; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Obesity management framework | Arm Label: Primary Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Obesity management framework | Intervention Type: BEHAVIORAL; Name: Obesity management framework; Assigned to Arm(s): Hospital, Primary Care
C: Arm Label: Obesity tools in electronic health record; Type: EXPERIMENTAL; Interventions: Other: Obesity tools in the electronic health record | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Obesity tools in the electronic health record; Assigned to Arm(s): Obesity tools in electronic health record
D: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle counseling (Fb) | Arm Label: Lifestyle counseling + activity watch; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle counseling + activity monitor (Fb+Act) | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling (Fb); Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling + activity monitor (Fb+Act); Assigned to Arm(s): Lifestyle counseling + activity watch

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Brief Summary: This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.

All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.

Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.


Options:
A: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
B: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
C: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: irinotecan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study
Brief Summary: The purpose of this research study is to identify barriers affecting self care in older patients with diabetes and to provide coping strategies for these barriers with help from a care manager (Geriatric Life Specialist) to improve clinical, economical, functional and psychosocial parameters.


Options:
A: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching
B: Arm Label: Geriatric diabetes team intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention for age specific barriers to self care | Arm Label: Attention Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intervention for age specific barriers to self care; Assigned to Arm(s): Geriatric diabetes team intervention group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Web-based care management | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Telephone and face-to-face care management | Arm Label: Arm 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Internet access alone | Intervention Type: PROCEDURE; Name: Web-based care management; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Telephone and face-to-face care management; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Internet access alone; Assigned to Arm(s): Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study
Brief Summary: The purpose of this research study is to identify barriers affecting self care in older patients with diabetes and to provide coping strategies for these barriers with help from a care manager (Geriatric Life Specialist) to improve clinical, economical, functional and psychosocial parameters.


Options:
A: Arm Label: Diabetes-Specific CBT (DS-CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes-Specific CBT (DS-CBT) | Arm Label: Standard Diabetes Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Diabetes Education | Intervention Type: BEHAVIORAL; Name: Diabetes-Specific CBT (DS-CBT); Assigned to Arm(s): Diabetes-Specific CBT (DS-CBT) | Intervention Type: BEHAVIORAL; Name: Standard Diabetes Education; Assigned to Arm(s): Standard Diabetes Education
B: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
C: Arm Label: Geriatric diabetes team intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention for age specific barriers to self care | Arm Label: Attention Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intervention for age specific barriers to self care; Assigned to Arm(s): Geriatric diabetes team intervention group
D: Intervention Type: BEHAVIORAL; Name: Nurse Case Management intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect and Cost Evaluation of a Multifaceted Approach Including Audit and Feedback With a Patient-centredness Questionnaire in Fertility Care.
Brief Summary: The purpose of this study is to evaluate the effects and costs of a multifaceted approach on the patient-centredness of fertility care and the quality of life of fertility patients.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Interventions for Dialysis Facilities | Intervention Type: BEHAVIORAL; Name: Behavioral Interventions for Dialysis Facilities; Assigned to Arm(s): Behavioral Intervention
B: Arm Label: Multifaceted approach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifaceted approach | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted approach; Assigned to Arm(s): Multifaceted approach
C: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
D: Arm Label: Arm 1; Type: OTHER; Interventions: Procedure: System level depression care quality improvement | Intervention Type: PROCEDURE; Name: System level depression care quality improvement; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Phase I Dose Finding Safety Study of a Thrombopoietin-receptor Agonist, Eltrombopag, in Patients With Myelodysplastic Syndrome Treated With Azacitidine
Brief Summary: Patients with Myelodysplastic Syndromes (MDS) often suffer from low platelet levels which may lead to bleeding complications. Treatment with cytotoxic agents can decrease the platelet levels further. Eltrombopag is a relatively new drug that increases the platelet level in the blood by working directly on the bone marrow. It is available for treatment of the disease Immunological Thrombocytopenic Purpura (ITP). In this study patients with MDS and low platelet levels that are treated with the cytotoxic agent Azacitidine will also receive Eltrombopag. The administration of Eltrombopag to MDS patients treated with Azacitidine may result in less dose reductions and less treatment delays for Azacitidine and may reduce the need for thrombocyte transfusions and lower the risk of bleeding complications.

This is a phase I study, meaning that our major goal is to investigate the safety and tolerability for Eltrombopag in this patient group. It will also generate a basis for a phase II-III-study.


Options:
A: Arm Label: Eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Eltrombopag
B: Arm Label: Dose level 1 500 AMG 531 (Part A - azacitidine); Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 (Romiplostim), Drug: Azacitidine | Arm Label: Dose level 1 750 AMG 531 (Part B - decitabine); Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 (Romiplostim), Drug: Decitabine | Arm Label: Dose level 2 750 AMG 531 (Part A - azacitidine); Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 (Romiplostim), Drug: Azacitidine | Arm Label: Placebo (Part A - azacitidine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Azacitidine | Arm Label: Placebo (Part B - decitabine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Decitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Part A - azacitidine), Placebo (Part B - decitabine) | Intervention Type: BIOLOGICAL; Name: AMG 531 (Romiplostim); Assigned to Arm(s): Dose level 1 500 AMG 531 (Part A - azacitidine), Dose level 1 750 AMG 531 (Part B - decitabine), Dose level 2 750 AMG 531 (Part A - azacitidine) | Intervention Type: DRUG; Name: Azacitidine; Assigned to Arm(s): Dose level 1 500 AMG 531 (Part A - azacitidine), Dose level 2 750 AMG 531 (Part A - azacitidine), Placebo (Part A - azacitidine) | Intervention Type: DRUG; Name: Decitabine; Assigned to Arm(s): Dose level 1 750 AMG 531 (Part B - decitabine), Placebo (Part B - decitabine)
C: Arm Label: Azacitidine + Eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Azacitidine + Eltrombopag
D: Arm Label: eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): eltrombopag

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects
Brief Summary: The purpose of this study is to determine the effect of theobromine on blood lipid parameters in healthy subjects. Secondary objectives are to determine the effect of cocoa and an interaction effect of cocoa and theobromine on blood lipid parameters.

Hypothesis: theobromine has a positive effect on blood lipid parameters.


Options:
A: Arm Label: flavanol rich intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Flavanol rich intervention | Arm Label: flavanol free intervention; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Flavanol free control | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavanol rich intervention; Assigned to Arm(s): flavanol rich intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavanol free control; Assigned to Arm(s): flavanol free intervention
B: Arm Label: Dark chocolate, dietary counselling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dark chocolate | Arm Label: Dietary counselling; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dark chocolate, Other: Dietary counselling | Intervention Type: DIETARY_SUPPLEMENT; Name: Dark chocolate; Assigned to Arm(s): Dark chocolate, dietary counselling, Dietary counselling | Intervention Type: OTHER; Name: Dietary counselling; Assigned to Arm(s): Dietary counselling
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control breakfast, Other: High glycemic index breakfast, Other: Low glycemic index breakfast | Arm Label: Intervention 1; Type: EXPERIMENTAL; Interventions: Other: Control breakfast, Other: High glycemic index breakfast, Other: Low glycemic index breakfast | Arm Label: Intervention 2; Type: EXPERIMENTAL; Interventions: Other: Control breakfast, Other: High glycemic index breakfast, Other: Low glycemic index breakfast | Intervention Type: OTHER; Name: Control breakfast; Assigned to Arm(s): Control, Intervention 1, Intervention 2 | Intervention Type: OTHER; Name: High glycemic index breakfast; Assigned to Arm(s): Control, Intervention 1, Intervention 2 | Intervention Type: OTHER; Name: Low glycemic index breakfast; Assigned to Arm(s): Control, Intervention 1, Intervention 2
D: Arm Label: Theobromine drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Theobromine | Arm Label: Cocoa drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cocoa | Arm Label: Placebo drink; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Cocoa and theobromine drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cocoa and theobromine | Intervention Type: DIETARY_SUPPLEMENT; Name: Theobromine; Assigned to Arm(s): Theobromine drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Cocoa; Assigned to Arm(s): Cocoa drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Cocoa and theobromine; Assigned to Arm(s): Cocoa and theobromine drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo drink

Answer: D